

TRADEMARK ASSIGNMENT COVER SHEET

Electronic Version v1.1
Stylesheet Version v1.2

ETAS ID: TM655309

SUBMISSION TYPE:	NEW ASSIGNMENT		
NATURE OF CONVEYANCE:	ASSIGNMENT OF THE ENTIRE INTEREST AND THE GOODWILL		
CONVEYING PARTY DATA			
Name	Formerly	Execution Date	Entity Type
Cadent Therapeutics, Inc. c/o Novartis Finance Corporation		12/16/2020	Corporation: DELAWARE
RECEIVING PARTY DATA			
Name:	Novartis AG		
Street Address:	CH-4002		
City:	Basel		
State/Country:	SWITZERLAND		
Postal Code:	4002		
Entity Type:	Corporation: SWITZERLAND		
PROPERTY NUMBERS Total: 2			
Property Type	Number	Word Mark	
Serial Number:	88592156	C CADENT THERAPEUTICS	
Serial Number:	88592166	CADENT THERAPEUTICS	
CORRESPONDENCE DATA			
Fax Number:	9198618913		
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>			
Phone:	9198618903		
Email:	mtepper@teiplaw.com		
Correspondent Name:	Maury M. Tepper, III		
Address Line 1:	3724 BENSON DR		
Address Line 4:	RALEIGH, NORTH CAROLINA 27609		
ATTORNEY DOCKET NUMBER:	CADENT		
NAME OF SUBMITTER:	Maury M. Tepper, III		
SIGNATURE:	/Maury M. Tepper, III/		
DATE SIGNED:	06/22/2021		
Total Attachments: 1			
source=US CADENT TO NOVARTIS ASSIGNMENT AGREEMENT 20210622#page1.tif			

OP \$65.00 88592156

ASSIGNMENT OF TRADEMARKS

This Assignment of Trademarks (the "Assignment") dated effective as of December 16th, 2020 (the "Effective Date"), is from Cadent Therapeutics, Inc., c/o Novartis Finance Corporation, One Health Plaza, East Hanover New Jersey 07936 (the "Assignor") to Novartis AG, CH-4002, Basel, Switzerland (the "Assignee").

WITNESSETH:

WHEREAS, Assignor is the owner of the following U.S. trademarks: Application Serial No. 88592166 for the mark CADENT THERAPEUTICS and Application Serial No. 88592156 for the mark CADENT THERAPEUTICS & Design (the "Marks"); and

WHEREAS, Assignor has agreed to assign, transfer and convey to Assignee all right, title and interest in and to the Marks, together with the goodwill of the business, and all common law rights, associated with the Marks; and

WHEREAS, Assignor and Assignee desire to confirm and record the assignment of the Marks;

NOW, THEREFORE, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged:

1. Assignor hereby assigns, transfers and conveys to Assignee all right, title and interest in and to the Marks, together with (1) the goodwill of the business symbolized by the Marks, (2) any and all common law rights, title and interest associated with the Marks, and (3) all causes of action, claims and demands and other rights for, or arising from, any infringement, including past infringements, of the Marks.

2. Assignor further agrees, without further consideration, to cause to be performed such other lawful acts and to be executed such confirmatory assignments and other legal documents as Assignee, or its counsel, may from time to time reasonably request to effect fully this Assignment and to permit Assignee to be duly recorded as the registered owner of each of the rights hereby conveyed.


IN WITNESS WHEREOF, the Assignor has executed this Assignment on the date set forth below, but effective as of the Effective Date.

ASSIGNOR:

ASSIGNEE:

Cadent Therapeutics, Inc.

Novartis AG



By: Mireille Valvasori and David Lossignol

By: Christine Repond and Marina Witschi

Title: Authorized Signatory

Title: Authorized Signatory

Date: 22 June, 2021

Date: 22 June, 2021